文献速递甲状腺疾病

国际甲状腺髓样癌分级系统在转移性患者中的验证

Validation of the International Medullary Thyroid Carcinoma Grading System in Patients with Distant Metastases.
PubMed 文献 · Thyroid · 2025-10-28

该单中心回顾性研究在99例转移性甲状腺髓样癌患者中验证IMTCGS的预后价值,发现IMTCGS高级别与更短的总生存期和系统治疗启动时间独立相关,Ki-67指数≥20%提示更差预后。

要点

  • IMTCGS高级别是转移性MTC患者OS和TTI的独立不良预后因素。
  • Ki-67指数≥20%患者OS显著劣于<5%和5-19%者。
  • RET-M918T突变与更差OS无关。

核心结论

  • IMTCGS是转移性MTC患者的强独立预后因素。
  • IMTCGS高级别且Ki-67指数≥20%的患者为预后最差的高危亚组。

研究设计与样本

  • 单中心回顾性研究,纳入2000至2024年在Gustave Roussy治疗的99例转移性MTC患者,基于原发肿瘤评估IMTCGS。

主要发现

  • 67例(67.7%)为IMTCGS高级别,较32例低级别患者年龄更大(p=0.009)且原发肿瘤更大(p<0.001)。
  • IMTCGS高级别患者中位OS较短(4.8 vs 13.9年;p=0.01),TTI也较短(1.0 vs 4.8年;p<0.001)。
  • 接受系统治疗的75例患者中,两组自治疗起始的OS相似(2.8 vs 3.89年;p=0.865)。
  • 多变量分析显示IMTCGS高级别和骨转移均独立与更短OS和TTI相关(两者p<0.05)。
  • Ki-67≥20%者OS为2.6年,劣于<5%者10.5年(HR=6.11;p<0.001)和5-19%者6.5年(HR=3.29;p=0.001)。

关键数值与推荐

  • IMTCGS高级别定义为符合以下至少一项:核分裂指数≥5/2 mm²、Ki-67增殖指数≥5%、肿瘤坏死;三项均缺如为低级别。

临床怎么用

  • 对转移性MTC患者可依据原发肿瘤IMTCGS分级和Ki-67指数进行风险分层。
  • IMTCGS高级别且Ki-67≥20%者预后最差,需加强监测和治疗决策。

局限性

  • 单中心回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The International Medullary Thyroid Carcinoma Grading System (IMTCGS) is a two-tier score that classifies high-grade medullary thyroid carcinoma (MTC) by the presence of at least one of the following features: mitotic index ≥5/2 mm2, Ki-67 proliferation index ≥5%, or tumor necrosis. Cases lacking all three features are classified as low-grade. This study aimed to validate the prognostic role of the IMTCGS in patients with metastatic MTC. The prognostic significance of a high proliferative index (Ki-67 index ≥20%) was also investigated. Methods: We conducted a monocentric retrospective study of 99 metastatic MTC patients treated at Gustave Roussy between 2000 and 2024, in whom the IMTCGS was assessed on the primary tumor. Results: IMTCGS high-grade tumors were found in 67 patients (67.7%), who were older (p = 0.009) and had larger primary tumors (p < 0.001) compared with 32 patients with low-grade tumors. Postoperative calcitonin levels, number of metastatic sites/patient, prevalence of synchronous metastases, and RET-M918T mutation were similar between groups. Median overall survival (OS) was shorter in patients with IMTCGS high-grade than low-grade (4.8 vs. 13.9 years; p = 0.01), as was time to systemic treatment initiation (TTI) (1.0 vs. 4.8 years; p < 0.001). However, among the 75 patients who received systemic therapy, OS from treatment initiation was similar between the two groups (2.8 vs. 3.89 years; p = 0.865). RET-M918T mutation was not associated with worse OS. On multivariable analysis, IMTCGS high-grade and bone metastases were independently associated with both shorter OS and TTI (p < 0.05 for both). Patients with Ki-67 index ≥20% had worse OS (2.6 years) compared with those with Ki-67 index <5% (10.5 years; hazard ratio [HR] = 6.11; p < 0.001) and 5-19% (6.5 years; HR = 3.29; p = 0.001). Conclusions: The IMTCGS is a strong independent prognostic factor in patients with metastatic MTC. Patients with IMTCGS high-grade tumors and Ki-67 index ≥20% represent a high-risk subgroup with the poorest prognosis.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Porcelli T, Moog S, Bani MA, et al. Validation of the International Medullary Thyroid Carcinoma Grading System in Patients with Distant Metastases. Thyroid. 2025. PMID: 41153085. doi:10.1177/10507256251388028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。